Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
|Videos|July 29, 2016
Counseling Points for Psoriasis Therapies
Debra Michaud, RN, MS, ARNP, FCP-C, MBA, senior clinician with MinuteClinic/CVS Health, discusses the key counseling points associated with psoriasis therapies.
Advertisement
Debra Michaud, RN, MS, ARNP, FCP-C, MBA, senior clinician with MinuteClinic/CVS Health, discusses the key counseling points associated with psoriasis therapies.
Advertisement
Related to this article
Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
Young adults who vaped daily but never smoked had lower flow-mediated dilation and peak oxygen uptake than peers who used neither product.
Pharmacists can reduce COVID-19 vaccine hesitancy through honest, nonjudgmental communication and by using every patient touchpoint as an opportunity to offer vaccination.
Expert Q&A: Geisinger Investigator Discusses Low Flu Vaccination Rates, ICU Findings in Older Adults
A study author explains how pharmacists can help close vaccination gaps in rural communities and what lower ICU admission rates among vaccinated older adults may mean.
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Advertisement
Advertisement
Trending on Pharmacy Times
1
COVID-19 ‘Is Not Done With Us’: Pharmacist Urges Continued Vaccination Ahead of Seasonal Peaks
2
Tarlatamab and Next-Generation Targeted Agents Headline ESMO 2026 Lung Cancer Data
3
PCSK9 Inhibition Lowers LDL-C in Patients With Kidney Disease
4
Ribociclib Survival Data Anchor a Sobering ESMO 2026 for Breast Cancer
5